TTUHSC School of Medicine
HomeSchool of MedicineCell Biology & BiochemistryFaculty

C. Patrick Reynolds, M.D. Ph.D.

C. Patrick Reynolds, M.D. Ph.D

Cancer Center Director

M.D. - University of Texas Southwestern Medical School, Dallas, TX
Ph.D. Cell Biology - University of Texas at Austin
Curriculum Vitae

Cell Biology and Biochemistry, Internal Medicine, and Pediatrics
Texas Tech University Health Sciences Center
3601 4th Street
Lubbock, Texas 79430

Phone: (806) 743-1558

Research Interests

Developmental therapeutics of adult and pediatric cancers in both laboratory and clinical studies. Types of drugs studied include retinoids, "vitamin A derivatives" as tumor-selective differentiation or cytotoxic agents and drugs such as depletors of glutathione or Bcl-2 inhibitors that overcome resistance to traditional cytotoxic agents. Other research identifies molecular mechanisms of drug resistance that may provide novel therapeutic targets in childhood and adult cancers, development of novel preclinical testing models for childhood and adult cancer drug development, and clinical trials testing novel therapeutic approaches for cancer.

To learn more, visit:

TTUHSC SOM Cancer Center
Children’s Oncology Group (COG) Cell Line and Xenograft Repository:
South Plains Oncology Consortium
Texas Cancer Cell Repository
DrugPath Drug to Molecular Pathway matching database

Selected Publications

(From > 200 peer-reviewed publications, H Index = 70) Full publications list: NCBI My Bibliography, Google Scholar

  • Mohrbacher A, Yang AS, Groshen S, Kummar S, Gutierrez ME, Kang MH, Tsao-Wei D, Reynolds CP, Newman E, Maurer BJ: Phase I study of fenretinide delivered intravenously in patients with relapsed or refractory hematologic malignancies: a California Cancer Consortium Trial. Clinical Cancer Res (In Press, 2017). PubMed
  • Makena MR, Koneru B, Nguyen TH, Kang MH, Reynolds CP: Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies. Molecular Cancer Therapeutics 16:649-661, 2017.PubMed
  • Chen NE, Maldonado V, Khankaldyyan V, Shimada H, Song MM, Maurer BJ, Reynolds CP: Reactive osygen species mediates the syngergistic activity of fenretinide combined with the microtubule inhibitor ABT-751 against multidrug-resistant recurrent neuroblastoma xenografts. Molecular Cancer Therapeutics 15:1-12, 2016. PubMed
  • Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada S, Reynolds CP: A Phase I New Approaches to Neuroblastoma Therapy study of buthionine sulfoximine and melphalan with autologous stem cells for recurrent/refractory high-risk neuroblastoma. Pediatr Blood Cancer 63:1349-56, 2016. PubMed
  • Sheard MA, Ghent MV, Kang MH, Cabral DJ, Lee JC, Khankaldyyan V, Ji L, Wu SQ, Sposto R, Asgharzadeh S, Reynolds CP: The Warburg effect is preserved by establishing new childhood acute lymphoblastic leukemia cell lines in physiologic oxygen tension. Exp Cell Res 334:78-89, 2015. PubMed
  • Reynolds CP, Kang MH, Maris JM, Kolb EA, Gorlick R Carol H, Lock R, Wu J, Keir ST, Kurmasheva RT, Houghton PJ, Smith MA: Initial Testing (Stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 62:1897-905, 2015. PubMed
  • Kang MH,  Wang J,  Makena M Lee JS Paz N, Hall CP, Song MM, Calderon RI, Cruz R Hindle A, Ko W,  Fitzgerald J,  Drummond DC, Triche TJ, Reynolds CP:  Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewings family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clinical Cancer Research 21:1139-50, 2015. PubMed
  • Tagde A, Singh H, Kang MH, Reynolds CP: Glutathione synthesis inhibitor buthionine sulfoximine synergized melphalan activity against preclinical models of multiple myeloma. Blood Cancer Journal, 18;4:e229, 2014. PubMed
  • Maurer BJ, Kang MH, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Villablanca JG, Czarnecki S, Beth Hasenauer B, Reynolds CP, Marachelian A: Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed neuroblastoma: A report from the NANT consortium. Pediatr Blood Cancer 60:1801-8, 2013. PubMed
  • Sausen M, Leary RJ, Wu J, Reynolds CP, Liu X, Maris J, Blackford A, Parmigiani G, Diaz LA, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, Hogarty MD: Genomic landscape of the childhood cancer neuroblastoma. Nature Genetics 45:12-17, 2013. PubMed
  • Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J, Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors. J Neurooncology 107:269-80, 2012. PubMed
  • Villablanca JG. London WB, Naranjo A, McGrady MS, Ames MM Joel M. Reid JM, McGovern RM, Buhrow SA, Stranzinger JH, Kitchen BJ, Sondel PM, Parisi M, Shulkin B, Yanik GA, Cohn S, Reynolds CP: Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the Children’s Oncology Group NSC #374551; IND# 40294. Clinical Cancer Research 17:6858-6866, 2011. PubMed
  • Fang H Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP: Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clinical Cancer Research 17:7093-104, 2011. PubMed
  • Kang MH, Smith MA, Morton CL, Nino Keshelava N, Houghton PJ, Reynolds CP: National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (EPUB Oct, 2010). PubMed
  • Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger RC, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM: Anti-GD2 antibody with GM- CSF, IL2 and isotretinoin for neuroblastoma: A Children’s Oncology Group (COG) phase III study. New England J Medicine 363:1324-1333, 2010. (Faculty of 1000 ranked this paper in top 2% of biology and medicine published papers.) PubMed
  • Maurer BJ, Kalous O, Yesair DW, Wu X, Vratilova J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP: Improved oral delivery of N-(4-hydroxyphenyl)retinamide with novel LYM-X-SORB™ organized lipid complex in mice. Clinical Cancer Research 13:3079-3086, 2007. PubMed
  • Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. Cancer Research 61:6185-6193, 2001. PubMed
  • Maurer BJ, Cabot MC, Reynolds CP: Synergistic cytotxicity in solid tumor cell lines of N-(4-hydroxypheynl)- retinamide and modulators of ceramide metabolism. J National Cancer Institute 92:1897-1908, 2000. PubMed
  • Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shamada H, Black CG, Brodeur GM, Gerbing R, Reynolds CP: Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. New England J Medicine 341:1165-1173, 1999. PubMed
  • Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Research 58:5396-5405, 1998. PubMed
  • Villablanca JG, Avramis V, Khan A, Matthay KK, Ramsay NKC, Seeger RC, Reynolds CP: Phase I trial of 13-cis- retinoic acid (cRA) in neuroblastoma patients following bone marrow transplantation (BMT). J Clinical Oncology 13:894-901, 1995. PubMed
  • Thiele CJ, Reynolds CP, Israel MA: Decreased expression of N myc precedes retinoic acid induced morphological differentiation of human neuroblastoma. Nature 313:404 407, 1985. PubMed

History & Education


1974 BA Biology - University of Texas at Austin
1979 MD University of Texas Southwestern Medical School, Dallas, TX
1979 PhD Cell Biology - University of Texas at Austin

Postdoctoral Research Fellowships:

1980 University of Texas Southwestern Medical School, Dallas, TX


1981 Pediatrics, National Naval Medical Center, Bethesda, Maryland


1988 Gold Medal for Research Achievement awarded by Nihon University, Tokyo, Japan
1992 Team Physician, 1992 USA Olympic Shooting Team, 25th Olympiad, Barcelona, Spain
2004 Eurand Prize for Novel Approaches in Oral Drug Delivery by the Controlled Release Society
2008 Best Clinical Paper Award, Advances in Neuroblastoma Research, Chiba, Japan
2011 Most cited paper in Clinical Cancer Research, 2009
  (Clinical Cancer Research 15:1126-1132, 2009)
2011 TTU System Chancellor's Council Distinguished Research Award
2012 Covenant Health Systems David R. Close, MD Endowed Chair in Oncology

National and State Leadership and Advisory Positions:

2000 - Present US FDA Special Government Employee
2003 - Present Editorial Board, Clinical Cancer Research
2007 - 2008 Natl. Cancer Inst. SBIR/STTR ZRG1 Cancer Drug Dev. + Therapeutics Study Section
2008 - Present Natl. Inst. Child Health and Development, Best Pharmaceuticals for Children Act Panel
2008 - 2013 Chartered member, Natl. Cancer Inst Drug Discovery + Molecular Pharm. Study Section
2009 - Present Advisory Committee on Childhood Cancer, Cancer Prevention Research Inst of Texas
2012 - Present FDA, NCI, NICHD BPCA Pediatric Oncology Working Group
2012 - 2014 University Advisory Committee, Cancer Prevention & Research Inst of Texas
2015 - Present Editorial Board, Molecular Cancer Therapeutics

Current Grant Support

Grants as Principal Investigator:

St. Baldricks COG Clinical Trial Access 01/12-12/17
Cancer Prevention &
Research Inst of Texas (CPRIT)
Telomere Maintenance Mechanisms in Neuroblastoma 12/16-12/20
Alex’s Lemonade Stand Foundation COG Cell Culture + Xenograft Repository 09/14-08/17
DOD OC150083 Novel Drug Combinations for Ovarian Cancer 05/16-03/18

Grants as Co-Investigator:

NCI RO1 CA168699 Kang, M (PI) Pharmacokinetics and Pharmacogenomics of 13-cis-RA in high-risk neuroblastoma 08/01/13-07/31/17
CPRIT RP170470 Kang, M (PI) OCT 4/c-MYC as a mechanism of resistance to 13-cis-retinoic acid in neuroblastoma 12/2016-12/2020
NCI R44 CA183316 Simpson PI A Phase I trial combining IV fenretinide and IV safingol to target overproduction of cytotoxic dihydroceramides in malignant cells 06/14-02/18
CPRIT CP130023 Love, PI Targeted Ceramide-Based Therapeutics 03/14-02/18